WO2011109726A3 - Anticorps homologues multispécifiques - Google Patents

Anticorps homologues multispécifiques Download PDF

Info

Publication number
WO2011109726A3
WO2011109726A3 PCT/US2011/027222 US2011027222W WO2011109726A3 WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3 US 2011027222 W US2011027222 W US 2011027222W WO 2011109726 A3 WO2011109726 A3 WO 2011109726A3
Authority
WO
WIPO (PCT)
Prior art keywords
specific antibodies
homologous
homologous multi
bind
relevant
Prior art date
Application number
PCT/US2011/027222
Other languages
English (en)
Other versions
WO2011109726A2 (fr
WO2011109726A9 (fr
Inventor
Jay M. Short
Hwai Wen Chang
Gerhard Frey
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of WO2011109726A2 publication Critical patent/WO2011109726A2/fr
Publication of WO2011109726A3 publication Critical patent/WO2011109726A3/fr
Publication of WO2011109726A9 publication Critical patent/WO2011109726A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne la production et l'optimisation d'anticorps homologues multispécifiques, des anticorps qui se distinguent par leur capacité à se lier à de multiples antigènes avec une spécificité et une affinité élevées. L'invention concerne également d'autres protéines multispécifiques qui se lient à plusieurs cibles.
PCT/US2011/027222 2010-03-05 2011-03-04 Anticorps homologues multispécifiques WO2011109726A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33953310P 2010-03-05 2010-03-05
US61/339,533 2010-03-05

Publications (3)

Publication Number Publication Date
WO2011109726A2 WO2011109726A2 (fr) 2011-09-09
WO2011109726A3 true WO2011109726A3 (fr) 2012-01-26
WO2011109726A9 WO2011109726A9 (fr) 2012-03-08

Family

ID=44542856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/027222 WO2011109726A2 (fr) 2010-03-05 2011-03-04 Anticorps homologues multispécifiques

Country Status (1)

Country Link
WO (1) WO2011109726A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902596TA (en) * 2010-07-16 2019-04-29 Bioatla Llc Novel methods of protein evolution
CA2872908C (fr) * 2012-05-10 2023-11-14 Gerhard Frey Anticorps monoclonaux multi-specifiques
CA2947605A1 (fr) 2014-05-13 2015-11-19 Bioatla, Llc Proteines biologiques conditionnellement actives
KR102615681B1 (ko) 2014-08-28 2023-12-18 바이오아트라, 인코퍼레이티드 변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
IL262404B2 (en) 2016-05-13 2024-04-01 Bioatla Llc Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
EP3806888B1 (fr) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
EP3870600A1 (fr) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Régulation de protéine accordable par er
WO2020185632A1 (fr) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Compositions d'anhydrase carbonique humaine 2 et procédés de régulation accordable
EP3966227A1 (fr) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
WO2021046451A1 (fr) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation de protéine accordable dhfr

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
WO2011009058A2 (fr) * 2009-07-17 2011-01-20 Bioatla, Llc Sélection et évolution intégrées simultanées de la performance et de l’expression d’un anticorps/d’une protéine chez des hôtes de production

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20070111260A1 (en) * 2005-10-14 2007-05-17 Medimmune, Inc. Cell display of antibody libraries
WO2011009058A2 (fr) * 2009-07-17 2011-01-20 Bioatla, Llc Sélection et évolution intégrées simultanées de la performance et de l’expression d’un anticorps/d’une protéine chez des hôtes de production

Also Published As

Publication number Publication date
WO2011109726A2 (fr) 2011-09-09
WO2011109726A9 (fr) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2011109726A3 (fr) Anticorps homologues multispécifiques
IN2014DN09417A (fr)
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
WO2013064701A3 (fr) Anticorps bispécifiques et méthodes d'isolement de ceux-ci
MX340556B (es) Anticuerpos biespecificos activables.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
WO2012125733A3 (fr) Méthodes de dépistage d'anticorps
WO2011056644A3 (fr) Anticorps anti-glp-1r et leurs utilisations
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
EP3470526A3 (fr) Anticorps qui se lient spécifiquement à l'alpha toxine de staphylococcus aureus et leurs procédés d'utilisation
WO2013188693A8 (fr) Constructions de liaison à l'antigène pour cd3
WO2011113019A3 (fr) Protéines ctla4 et leurs utilisations
WO2011097301A3 (fr) Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
WO2014189973A3 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
WO2014150877A3 (fr) Anticorps anti-tau et leurs procédés d'utilisation
WO2014125374A3 (fr) Anticorps anti-tnf alpha hautement galactosylés et leurs utilisations
WO2011047146A3 (fr) Procédés de maturation d'affinité d'anticorps
UA111818C2 (uk) Антитіло проти csf-1r
WO2014106015A3 (fr) Compositions protéiques à liaison multivalente
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2012131555A3 (fr) Immunoglobulines hétéro-dimériques
EA201201016A1 (ru) Антидоты антикоагулянтов
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
WO2014078268A8 (fr) Anticorps anti-hémagglutinine et leurs procédés d'utilisation
EA201291065A1 (ru) Антитела против vla-4

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11751433

Country of ref document: EP

Kind code of ref document: A2